



Used in Lieu of PTO/SB/08A/B
(Based on PTO 01-08 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,580
				Filing Date	September 12, 2005
				First Named Inventor	Patricia Lynne Conway
				Art Unit	1651
				Examiner Name	I. Marx
Sheet	1	of	3	Attorney Docket Number	BSWV-P01-008

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-6,596,389		Hallett et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-01/97821	12-27-2001	Mucoprotec Pty Ltd et al.		
	BB	WO-02/34273	05-02-2002	Atheromastat Pty Ltd et al.		
	BC	WO-03/068250	08-21-2003	Dermavri Pty Ltd et al.		
	BD	WO-00/71139	11-30-2000	Reid Gregor et al.		
	BE	WO-01/52912	07-26-2001	Procter & Gamble et al.		
	BF	WO-02/45726	06-13-2002	PI Bio Co Ltd et al.		
	BG	JP-09-263539	10-07-1997	Nichinichi Seiyaku Kk		
	BH	JP-09-002959	01-07-1997	Yakult Honsha Kk		
	BI	JP-2000-095697	04-04-2000	Advance Co Ltd		
	BJ	JP-2000-095698	09-06-1999			
	BK	JP-2000-086524	03-28-2000	Shadan Seirankai		
	BL	JP Sho-63-179829	07-23-1988	Advance Co Ltd		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	"Gastrointestinal health- Pharmacy's gut reaction," The Australian Journal of Pharmacy, vol. 85, May 2004, pp 323-29.	
	CB	"L. fermentum PCC™ is not the same as other probiotics" The Australian Journal of Pharmacy, vol. 85, October 2004, pp xxx.	
	CC	"Maintaining good intestinal health with proTract®" The Australian Journal of Pharmacy, vol. 85, November 2004, pp 880-81.	
	CD	"Probiotics: How to choose and how to use them," The Australian Journal of Pharmacy, vol. 85, June 2004, pp 408-11.	
	CE	"Probiotics: their use for gastrointestinal conditions," The Australian Journal of Pharmacy, vol. 85, July 2004, pp 540-543.	
	CF	"Probiotics: their role in immunomodulation and extraintestinal conditions," The Australian Journal of Pharmacy, vol. 85, August 2004, pp 640-43.	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,580
				Filing Date	September 12, 2005
				First Named Inventor	Patricia Lynne Conway
				Art Unit	1651
				Examiner Name	I. Marx
Sheet	2	of	3	Attorney Docket Number	BSWV-P01-008

CG	"Pro-Tract™ IBS-relief of symptoms of medically diagnosed IBS," The Australian Journal of Pharmacy, vol. 85, September 2004, pp 722.	
CH	"Scientific evidence behind new protract for Atopic Dermatitis," The Australian Journal of Pharmacy, vol. 86, April 2005, pp 236-237.	
CI	Amezcuca et al. "Effects on growth performance, feed efficiency, and health of weanling pigs fed fermented liquid whey inoculated with lactic acid bacteria that inhibit Escherichia coli in vitro" Journal of Swine Health and production, 15:6, 2007, 320-329	
CJ	Anukam, et al. "16S rRNA gene sequence and phylogenetic tree of lactobacillus species from the vagina of healthy Nigerian women," African Journal of Biotechnology v. 4, 1222-1227, 2005.	
CK	Blomberg et al., "Inhibition of Adhesion of Escherichia coli K88 to Piglet Ileal Mucus by Lactobacillus spp." Applied and Environmental Microbiology, 1993, vol. 69(1), pp 34-39.	
CL	Charteris et al., "Development and application of an in vitro methodology to determine the transit tolerance of potentially probiotic Lactobacillus and Bifidobacterium species in the upper human gastrointestinal tract," Journal of Applied Microbiology, vol. 84, no. 5, May 1998, pp 759-768.	
CM	Cross et al., Can Immunoregulatory Lactic Acid Bacteria be used as Dietary Supplements to Limit Allergies?, International Archives of Allergy and Immunology, vol. 125, 2001, pp 112-119.	
CN	Dahl et al., "Once-daily topical metronidazole cream formations in the treatment of the paules and pustules of rosacea" Journal of the American Academy of Dermatology, 2001, vol. 45, pp 723-30.	
CO	Dahl, et al. "Topical metronidazole maintains remissions of rosacea," Archives of Dermatology, 1998, vol. 134, pp 679-83.	
CP	Feldman et al., "Women commonly seek care for resoacea: dermatologists frequently provide the care," Cutis 2001, vol. 68, pp 156-60.	
CQ	French, Peter W., "Atopic dermatitis-the connection with the gastrointestinal tract and the use of probiotics as a novel therapeutic option," The Australian Journal of Pharmacy, vol. 86, June 2005, pp 426-29.	
CR	French, Peter, "PCC® (Lactobacillus fermentum VRI 003 is the probiotic of choice for infant atopic dermatitis," Probiomix Ltd Monograph No. 4 2006.	
CS	Gardiner et al. "Persistence of Lactobacillus fermentum RC-14 and Lactobacillus rhamnosus GR01 but Not L. rhamnosus GG in the human vagina as demonstrated by randomly amplified polymorphic DNA" Clinical and Diagnostic Laboratory Immunology, 2002, 92-96.	
CT	Halbert et al., "Probiotics help reduce severity of atopic dermatitis," Clinical Research Abstracts for Pediatricians, The Journal of Pediatrics, January 2006, pp 143-44.	
CU	Heinemann et al., "Purification and characterization of a surface-binding protein from lactobacillus fermentum RC-14 that inhibits adhesion of Enterococcus faecalis 113," FEMS Microbiology Letters, 2000, vol. 190, pp 177-80.	
CV	Hoting et al., "The treatment of rosacea with isotretinoin" International Journal of Dermatology, 1986, vol. 25, pp 660-3.	
CW	Howard et al. "Identification of Collagen-Binding Proteins in Lactobacillus spp. With Surface-Enhanced Laser Desorption/Ionization-Time of Flight ProteinChip Technology" Applied and Environmental Microbiology, 2000, 4396-4400.	
CX	Isolauri et al., "Probiotics in the management of atopic aczema" Clinical and Experimental Allergy, 2000, vol. 30, pp 1604-1610.	
CY	Kalliomaki et al., "Probiotics in primary prevention of atopic disease; a randomized placebo-controlled trial" The Lancet, vol. 357, April 7, 2001, pp 1076-1079.	
CZ	Mahrle et al., "Roaccutan in acne and rosacea," Z Haukr, 1985, vol. 60, 120, 125-34. ABSTRACT ONLY.	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,580
				Filing Date	September 12, 2005
				First Named Inventor	Patricia Lynne Conway
				Art Unit	1651
				Examiner Name	I. Marx
Sheet	3	of	3	Attorney Docket Number	BSWV-P01-008

	CA1	Majamaa et al., "Probiotics: a novel approach in the management of food allergy" The Journal of Clinical Immunology, vol. 99(2). Feb. 1997, pp 179-85.	
	CB1	Mombelli et al., "The use of probiotics in medical practice" International Journal of Antimicrobial Agents, vol. 16, 2000, pp 531-536.	
	CC1	Murch S.H. "Toll of allergy reduced by probiotics," The Lancet, vol. 357, April 7, 2001, pp 1057-1059.	
	CD1	Pessi et al., Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG, Clinical and Experimental Allergy, 2000 vol. 30, pp 1804-1808.	
	CE1	Plant and Conway, "Association of Lactobacillus spp. with Peyer's Patches in Mice," Clinical and Diagnostic Laboratory Immunology, 2001, vol. 8(2), pp. 320-4.	
	CF1	Prescott et al., "Clinical effects of probiotics are associated with increased interferon-γ responses in very young children with atopic dermatitis," Clin Exp Allergy, vol. 35, 2005, 1557-64.	
	CG1	Reid and Bruce, "Probiotics to prevent urinary tract infections: the rationale and the evidence" World J. Urology 2006;24:28-32.	
	CH1	Reid and Hammond, "Probiotics: some evidence of their effectiveness" Canadian Family Physician v. 51 2005 1497-1493.	
	CI1	Wanke, C.A., Do probiotics prevent childhood diseases?, BMJ 2001;322; pp. 1318-1319.	
	CJ1	Weston et al., "Effects of probiotics on atopic dermatitis: a randomized controlled trial," Arch Dis Child., 29 April 2005, 16 pages.	
	CK1	Yang et al., Probiotics and Application, China Dairy Industry, vol. 28, no. 1, Feb. 2000, pp. 29-31.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.